Protein kinase C beta inhibition: A novel therapeutic strategy for diabetic microangiopathy.
about
Presence and Risk Factors for Glaucoma in Patients with Diabetes.Proteomic Analysis of Vascular Endothelial Cells-Effects of Laminar Shear Stress and High Glucose.Priming of eosinophils by GM-CSF is mediated by protein kinase CbetaII-phosphorylated L-plastin.Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure.Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitusDistinct and complementary roles for α and β isoenzymes of PKC in mediating vasoconstrictor responses to acutely elevated glucoseHigh glucose-induced Nox1-derived superoxides downregulate PKC-betaII, which subsequently decreases ACE2 expression and ANG(1-7) formation in rat VSMCsAlpha-lipoic Acid and diabetic neuropathy.Opportunity nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease.Protein kinase C βII in diabetic complications: survey of structural, biological and computational studies.Protein kinase C inhibitors: a patent review (2010 - present).Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance.Vascular dysfunction in Type 2 diabetes: emerging targets for therapy.Glucose enhances expression of TRPC1 and calcium entry in endothelial cells.High glucose/lysophosphatidylcholine levels stimulate extracellular matrix deposition in diabetic nephropathy via platelet‑activating factor receptor.Cellular death, reactive oxygen species (ROS) and diabetic complications.PKCβ inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfunction in rats with streptozotocin-induced diabetes.Structural basis of conformational variance in phosphorylated and non-phosphorylated states of PKCβII.
P2860
Q30244246-23B4F1EE-6D3D-4984-A3D4-62B9E9ECA1E4Q33637397-E3B79B8C-94DE-4FF1-9CC0-6E1A714E1554Q33883158-74D5091D-BE96-49AD-9D82-374635772B78Q34396881-0FE3950C-0269-4782-9560-632BA779C54CQ34931190-B29C7BAF-9333-4703-8158-C4F4EFFD28FEQ36599646-5AA660FC-7B70-4558-8387-F70ABE35EB08Q37088267-EEB7D15D-EC62-4145-B954-15A1D57C591EQ37665315-532B4D17-2065-4BB1-B3CC-AAB3E6E2A11BQ37978891-EDEAD6D1-4C71-4619-835E-2F7A9B91DF1CQ37992101-BF784106-FAF9-4F19-9704-25807B1C16F1Q38116565-764E06BE-34BD-4585-B4AC-519AB1E2EF54Q39014996-41494661-E5D3-4B95-A608-4DEA989906E5Q41121422-14123251-06F8-48A7-8A99-9D580AE9FEADQ42461828-5EEDEE0D-40F9-4308-BEA7-5E1A75E51FC3Q47329024-21011551-6226-434A-AD0C-61B6F78090E2Q49679592-B66AC34E-0AD7-439D-9A1B-4C6885D35B84Q54563159-CEBE8C5F-D2A5-46BF-BE27-684E55678834Q55072903-1EDD899A-8894-4605-B401-EDB7E2F88DE1
P2860
Protein kinase C beta inhibition: A novel therapeutic strategy for diabetic microangiopathy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Protein kinase C beta inhibiti ...... for diabetic microangiopathy.
@ast
Protein kinase C beta inhibiti ...... for diabetic microangiopathy.
@en
type
label
Protein kinase C beta inhibiti ...... for diabetic microangiopathy.
@ast
Protein kinase C beta inhibiti ...... for diabetic microangiopathy.
@en
prefLabel
Protein kinase C beta inhibiti ...... for diabetic microangiopathy.
@ast
Protein kinase C beta inhibiti ...... for diabetic microangiopathy.
@en
P2860
P356
P1476
Protein kinase C beta inhibiti ...... for diabetic microangiopathy.
@en
P2093
Iskandar Idris
Richard Donnelly
P2860
P304
P356
10.3132/DVDR.2006.026
P407
P577
2006-12-01T00:00:00Z